Clinical Follow-up Study of TIVOLI Biodegradable Sirolimus-Eluting Stents and Endeavor Zotalimus-Eluting Stents in Treating Coronary Artery Disease Patients

DOU Ke-fei,XU Bo,HAN Ya-ling,LU Shu-zheng,YANG Yue-jin,HUO Yong,WANG Le-feng,CHEN Yun-dai,WANG Hai-chang,LI Wei-min,CHEN Ji-yan,WANG Lei,WANG Yong,GE Jun-bo,LI Wei,GAO Run-lin

DOI: https://doi.org/10.3969/j.issn.1000-3614.2012.05.005

2012-01-01

Abstract:Objective:To evaluate the efficacy and safety of TIVOLI biodegradable polymer coated sirolimus-eluting stents(TIVOLI stents) in treating coronary artery disease(CAD) patients. Methods:We conducted a prospective multicenter clinical trial to demonstrate the no-inferiority of TIVOLI stents to Endeavor zotalimus-eluting stents(Endeavor stents) in late lumen loss.Our work included two groups as TIVOLI group,n=168 and ENDEAVOR group,n=156.The primary end point was angiographic in-stent late lumen loss at 240 days.The secondary end point was 1～3 years clinical follow-up of major adverse cardiac events(MACE) as cardiac death,myocardial infarction,target lesion revascularization(TLR) and in-stent thrombosis. Results: The angiographic late lumen loss at 240 days in TIVOLI group was lower than that in Endeavor group,P0.05～001.The 1～3 years post-operational TLR in TIVOLI group were all lower than those in Endeavor group,P0.05～001. Conclusion:TIVOL stents was superior to Endeavor stents in terms of late lumen loss at 240 days after stent implantation,it also had lower in-stent re-stenosis rate and lower TLR at 3 years after stent implantation.